US EditionIndia's Biocon could fill gap created by reported Novo insulin pen retreat which risks drug access to kids with diabetes
Summary by newsindiatimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
India's Biocon could fill gap created by reported Novo insulin pen retreat which risks drug access to kids with diabetes
Poster of novolog flexpen instructions for use. PHOTO: Novomedlink.com May 13, 2025 – (Bloomberg) — Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless non-patented drugmakers such as Biocon Ltd. step in to plug the gap in a $34 billion market. The Danish drugmaker has started phasing out the easy-to-use insulin pens in some countries, including India, forcing young people to sh…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
